Bottom line
Is BHCFX a good fund? The bottom line
BHCFX is the Retail share class of Baron Health Care Fund, a managed health care sector mutual fund from Baron Select.
It charges 1.1% — about $110 a year on every $10,000 invested, more expensive than 63% of health care sector funds we track.
It returned +10.0% over one year, +2.5% a year over five years (as of Dec 31, 2025, per its prospectus).
With $114 million in net assets and 43 holdings, its largest position is Eli Lilly & Co (13.7%) and the top 10 make up 50.6% of the portfolio.
The closest lower-cost alternative we found is PRHSX (0.83%, 50% top-holdings overlap).
What to watch
- 5-year return in the bottom quarter of its category
- Concentrated: top 10 holdings are 50.6% of assets
- 12b-1 marketing fee of 0.25% a year
Updated Nov 19, 2026
What BHCFX invests in
The investment goal of Baron Health Care Fund (the Fund) is capital appreciation.
The Fund is a non-diversified fund that, under normal circumstances, invests at least 80% of its net assets in equity securities of companies engaged in the research, development, production, sale, delivery or distribution of products and services related to the health care industry. The Adviser uses various criteria to determine whether an issuer is engaged in activities related to the health care industry, including whether: (1) the issuer derives 50% or more of its revenues from activities in the health care industry; or (2) the issuer devotes 50% or more of its assets to producing sales from the health care industry. These companies may include, among others, pharmaceutical companies, biotechnology companies, life sciences tools and services companies, health care equipment companies, health care supplies companies, managed health care companies, health care services companies…
From the fund's prospectus (filed Apr 30, 2026).
BHCFX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| BHCFX | +10.0% | +2.5% | — |
| Health Care Sector median | +14.5% | +4.2% | +7.9% |
Source: Fund prospectus, as of Dec 31, 2025
What BHCFX costs
On a $10,000 investment, BHCFX's 1.1% expense ratio costs about $110 a year. The prospectus estimates $1,340 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.
BHCFX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Eli Lilly & Co | 13.66% |
| 2 | Mettler-Toledo International Inc | 5.60% |
| 3 | Johnson & Johnson | 5.56% |
| 4 | Argenx SE | 4.23% |
| 5 | Thermo Fisher Scientific Inc | 3.91% |
| 6 | Roivant Sciences Ltd | 3.88% |
| 7 | Teva Pharmaceutical Industries Ltd | 3.86% |
| 8 | Welltower Inc | 3.38% |
| 9 | UnitedHealth Group Inc | 3.28% |
| 10 | RadNet Inc | 3.24% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 50.6% of the fund. See all top 25 holdings and asset mix →